Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults.
The FDA has approved eplontersen (Wainua; AstraZeneca, Ionis Pharmaceuticals) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adults. This approval makes eplontersen the only medicine to be approved for the treatment of ATTRv-PN that can be self-administered with an auto-injector.
In January 2024, eplontersen was granted Orphan Drug Designation in the U.S. by the FDA. In addition to the NEURO-TTRansform study, eplontersen
FDA approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Eplontersen
Wainua will enter the US market in January 2024 after positive Phase III data landed it an FDA approval for ATTRv-PN (eplontersen) for a
The FDA has approved eplontersen (Ionis, AstraZeneca), a ligand-conjugated antisense oligonucleotide, for the treatment of adult patients with hereditary
(Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA (eplontersen) for
Wainua (eplontersen) injection, for subcutaneous use. US Food and Drug Administration (FDA) approval information. Revised December 2024.
WAINUA (eplontersen) injection, for subcutaneous use This label may not be the latest approved by FDA. For current labeling information, please visit https
Comments